me 2303 profile

ME 2303: structure given in first source; RN given refers to (2S-cis)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	115362
MeSH ID	M0164474

Synonym
fad-104
me-2303
heptanedioic acid, mono(2-(4-((2,6-dideoxy-2-fluoro-alpha-l-talopyranosyl)oxy)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-2-naphthacenyl)-2-oxoethyl) ester, (2s-cis)-
me 2303
me2303
7-o-(2,6-dideoxy-2-fluoro-alpha-l-talopyranosyl)pimelyladriamycinone
7-o-(2,6-dideoxy-2-fluoro-alpha-l-talopyranosyl)adriamycinone-14-o-hemipimelate
7-[2-[(2s,4s)-4-[(2r,3r,4r,5s,6s)-3-fluoro-4,5-dihydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1h-tetracen-2-yl]-2-oxoethoxy]-7-oxoheptanoic acid
7-o-(2,6-dideoxy-2-fluoro-alpha-talopyranosyl)pimelyladriamcycinone
me2302
unii-bd89kyn03d
bd89kyn03d ,
fad 104
116521-53-0
DTXSID70151417
mej2303
fad104
7-(2-((2r,4s)-4-((2s,3s,4r,5s,6s)-3-fluoranyl-6-methyl-4,5-bis(oxidanyl)oxan-2-yl)oxy-7-methoxy-2,5,12-tris(oxidanyl)-6,11-bis(oxidanylidene)-3,4-dihydro-1h-tetracen-2-yl)-2-oxidanylidene-ethoxy)-7-oxidanylidene-heptanoic acid
fluoro-doxorubicin
mej-2303

Excerpt	Reference	Relevance
"ME 2303 is a new anthracycline analog which differs from adriamycin in the sugar moiety. "	( [Evaluation of cardiotoxicity in new anthracycline analog ME 2303. ME 2303 Study Group]. Ariyoshi, Y; Furue, H; Kimura, I; Majima, H; Niitani, H; Ogawa, M; Okuma, K; Shimoyama, M; Taguchi, T; Wakui, A, 1991)	1.97

Excerpt	Reference	Relevance
"ME 2303 displays a higher antitumor activity against L 1210 and P 388 Leukemia than adriamycin."	( [Evaluation of cardiotoxicity in new anthracycline analog ME 2303. ME 2303 Study Group]. Ariyoshi, Y; Furue, H; Kimura, I; Majima, H; Niitani, H; Ogawa, M; Okuma, K; Shimoyama, M; Taguchi, T; Wakui, A, 1991)	1.25

Excerpt	Reference	Relevance
" administration of M2, 5 mg kg(-1), to rats, the mean plasma concentrations of M2 were detected up to 60 min with a mean terminal half-life of only 38."	( Comparison of pharmacokinetics of M1, M2, M3, and M4 after intravenous administration of DA-125 or ME2303 to mice and rats. New adriamycin analogues containing fluorine. Kim, WB; Lee, MG; Lee, SD; Lee, WI; Shim, HJ; Yang, J; Yoon, EJ, 1996)	0.29

Excerpt	Relevance	Reference
" The dosage of ME 2303 was 35 or 50 mg/kg and that of doxorubicin was 5 mg/kg."	( [Antitumor activities of ME 2303 on human gastrointestinal cancer xenografted to nude mice]. Fujita, F; Fujita, M; Taguchi, T, 1990)	0.94

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	4 (18.18)	18.7374
1990's	18 (81.82)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (4.35%)	5.53%
Reviews	3 (13.04%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	19 (82.61%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
histidine Histidine: An essential amino acid that is required for the production of HISTAMINE.. L-histidine : The L-enantiomer of the amino acid histidine.. histidine : An alpha-amino acid that is propanoic acid bearing an amino substituent at position 2 and a 1H-imidazol-4-yl group at position 3.	1.99	1	0	amino acid zwitterion; histidine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	algal metabolite; Escherichia coli metabolite; human metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	3.08	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
fluorine Fluorine: A nonmetallic, diatomic gas that is a trace element and member of the halogen family. It is used in dentistry as fluoride (FLUORIDES) to prevent dental caries.	1.97	1	0	diatomic fluorine; gas molecular entity	NMR chemical shift reference compound
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	5.38	2	1	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
irinotecan [no description available]	3.08	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
7-o-(2,6-dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride 7-O-(2,6-Dideoxy-2-fluoro-alpha-talopyranosyl)adriamycinone- 14-beta-alaniate hydrochloride: structure in first source	1.99	1	0
7-o-(2,6-dideoxy-2-fluorotalopyranose)adriamycinone 7-O-(2,6-dideoxy-2-fluorotalopyranose)adriamycinone: structure given in first source	1.97	1	0
menogaril Menogaril: A semisynthetic anthracycline with the amino sugar on the D ring. It displays broad-spectrum antineoplastic activity against a variety of tumors.	5.38	2	1
nadp [no description available]	1.99	1	0
amrubicin amrubicin: structure in first source; a 9-amino-anthracycline antibiotic. amrubicin : A synthetic anthracycline antibiotic with molecular formula C25H25NO9. A specific inhibitor of topoisomerase II, it is used (particularly as the hydrochloride salt) in the treatment of cancer, especially lung cancer, where it is a prodrug for the active metabolite, ambrucinol.	5.67	3	1	anthracycline antibiotic; methyl ketone; primary amino compound; quinone; tetracenes	antineoplastic agent; prodrug; topoisomerase II inhibitor
morpholinoanthracycline mx2 morpholinoanthracycline MX2: structure given in first source	4.87	2	1
pirarubicin [no description available]	1.98	1	0	anthracycline
carubicin Carubicin: A very toxic anthracycline-type antineoplastic related to DAUNORUBICIN, obtained from Actinomadura carminata.. carminomycin(1+) : An anthracyline cation that is the conjugate acid of carminomycin, obtained by protonation of the amino group.	4.87	2	1	anthracycline cation

Condition	Relationship Strength	Studies	Trials
Cancer of Ovary [description not available]	1.98	1	0
Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.	1.98	1	0
Leucocythaemia [description not available]	2.9	1	0
Germinoblastoma [description not available]	2.9	1	0
Acute Disease Disease having a short and relatively severe course.	2.9	1	0
Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)	2.9	1	0
Lymphoma A general term for various neoplastic diseases of the lymphoid tissue.	2.9	1	0
Cancer of Liver [description not available]	2.38	2	0
Cancer of Pancreas [description not available]	1.98	1	0
Liver Neoplasms Tumors or cancer of the LIVER.	2.38	2	0
Pancreatic Neoplasms Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).	1.98	1	0
Benign Neoplasms, Brain [description not available]	4.28	1	1
Experimental Leukemia [description not available]	4.28	1	1
Cancer of Stomach [description not available]	4.68	2	1
Acute Myelogenous Leukemia [description not available]	4.68	2	1
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	4.28	1	1
Stomach Neoplasms Tumors or cancer of the STOMACH.	4.68	2	1
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	4.68	2	1
Sarcoma 180 An experimental sarcoma of mice.	1.99	1	0
Carcinoma, Oat Cell [description not available]	2.89	1	0
Carcinoma, Non-Small Cell Lung [description not available]	2.89	1	0
Cancer of Lung [description not available]	4.14	6	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.89	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	4.14	6	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	2.89	1	0
Cancer of Colon [description not available]	2.38	2	0
Colonic Neoplasms Tumors or cancer of the COLON.	2.38	2	0
Leukemia L 1210 [description not available]	2.38	2	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	2.38	2	0
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	1.97	1	0
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	1.97	1	0
Adenocarcinoma, Basal Cell [description not available]	2.38	2	0
Experimental Hepatoma [description not available]	2.38	2	0
Condition, Preneoplastic [description not available]	1.97	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	2.38	2	0
Precancerous Conditions Pathological conditions that tend eventually to become malignant.	1.97	1	0
Benign Neoplasms [description not available]	1.97	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1.97	1	0
Necrosis The death of cells in an organ or tissue due to disease, injury or failure of the blood supply.	1.97	1	0
Colorectal Cancer [description not available]	1.97	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	1.97	1	0
Experimental Neoplasms [description not available]	2.38	2	0
B16 Melanoma [description not available]	1.97	1	0
EHS Tumor [description not available]	1.97	1	0

me 2303

Description

Cross-References

Synonyms (20)

Research Excerpts

Overview

Actions

Pharmacokinetics

Dosage Studied

Research

Studies (22)

Market Indicators

Research Demand Index: 11.72

Study Types

me 2303

Description

Cross-References

Synonyms (20)

Research Excerpts

Overview

Actions

Pharmacokinetics

Dosage Studied

Research

Studies (22)

Market Indicators

Research Demand Index: 11.72

Study Types

Related Drugs (13)

Related Conditions (44)